Out-Of-Pocket’s 2025 Predictions | Out-Of-Pocket

Key Takeaways

• GLP‑1 pricing pressure will improve obesity drug access
• Healthcare AI models will prioritize explainability over generic performance
• HSAs likely to detach from high‑deductible plans
• New APCM codes could generate $100 M Medicare revenue in 2025
• Retail pharmacy closures accelerate shift to mail‑order and delivery

Pulse Analysis

The obesity‑drug landscape is poised for a price correction as new GLP‑1 formulations enter the market and manufacturers experiment with outcomes‑based reimbursement. Payers, especially Medicaid and Medicare, are likely to narrow coverage to high‑risk groups, but the net effect will be a broader cost‑effectiveness narrative that could drive adoption among patients with severe obesity and comorbidities. This shift not only improves health outcomes but also creates a more sustainable financial model for insurers and providers.

Artificial intelligence in health care is entering a bifurcation phase. General‑purpose foundation models will continue to power consumer‑facing tools, while enterprise‑grade, health‑specific models will prioritize accuracy, auditability and data security. Companies that open‑source model weights for client fine‑tuning will gain a competitive edge, and price competition is expected to push AI services below traditional offshore outsourcing rates. However, the rapid deployment of these models also raises litigation risk around copyright, malpractice and algorithmic bias, prompting firms to invest heavily in compliance and governance.

Policy and market dynamics are converging to reshape financing and delivery. A pro‑HSA administration could decouple accounts from high‑deductible plans and raise contribution limits, expanding a tax‑advantaged savings vehicle for a broader population. Simultaneously, CMS’s new Advanced Primary Care Management codes promise $100 million in Medicare reimbursements, incentivizing integrated chronic‑care services. Meanwhile, a potential FDA split into food and drug agencies may tighten food safety oversight while preserving drug review rigor. Liquidity is returning to digital‑health firms via IPOs, yet retail pharmacy chains face accelerating closures, pushing patients toward mail‑order and on‑demand delivery solutions. These forces together signal a more data‑driven, financially flexible, and patient‑centric health‑care ecosystem by 2025.